​

Funding Round

Series C - Sionna Therapeutics

Series C - Sionna Therapeutics

Investment Firm

Overview

Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).

Announced Date

Mar 06, 2024

Closed on Date

Mar 06, 2024

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Enavate Sciences

Enavate Sciences

Enavate Sciences is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

9

Investor Name
Participant InvestorThe Rise Fund
Participant InvestorRA Capital Management
Participant InvestorOrbiMed
Participant InvestorT. Rowe Price
Participant InvestorAtlas Venture

Round Details and Background

Sionna Therapeutics raised $182000000 on 2024-03-06 in Series C

Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Apr 19, 2022
Series B - Sionna Therapeutics
6-110.0M
Mar 06, 2024
Series C - Sionna Therapeutics
10-182.0M

Recent Activity

There is no recent news or activity for this profile.